Metsera [MTSR] vs Corcept Therapeutics [CORT] Detailed Stock Comparison

Metsera Inc.

NASDAQ
Loading...

Corcept Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Metsera Inc. wins in 4 metrics, Corcept Therapeutics Inc. wins in 10 metrics, with 0 ties. Corcept Therapeutics Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Metsera Inc. Corcept Therapeutics Inc. Better
P/E Ratio (TTM) -34.73 56.37 Corcept Therapeutics Inc.
Price-to-Book Ratio 21.98 7.38 Corcept Therapeutics Inc.
Debt-to-Equity Ratio 0.84 0.94 Metsera Inc.
PEG Ratio N/A -2.72 N/A
EV/EBITDA -26.34 96.45 Corcept Therapeutics Inc.
Profit Margin (TTM) 0.00% 13.09% Corcept Therapeutics Inc.
Operating Margin (TTM) 0.00% 2.22% Corcept Therapeutics Inc.
EBITDA Margin (TTM) N/A 2.22% N/A
Return on Equity -134.66% 15.02% Corcept Therapeutics Inc.
Return on Assets (TTM) -38.77% 3.34% Corcept Therapeutics Inc.
Free Cash Flow (TTM) $-100.08M $141.79M Corcept Therapeutics Inc.
1-Year Return 166.04% -10.40% Metsera Inc.
Price-to-Sales Ratio (TTM) N/A 6.36 N/A
Enterprise Value $6.98B $4.43B Metsera Inc.
EV/Revenue Ratio N/A 5.82 N/A
Gross Profit Margin (TTM) N/A 98.74% N/A
Revenue per Share (TTM) $0 $7 Corcept Therapeutics Inc.
Earnings per Share (Diluted) $-2.99 $0.80 Corcept Therapeutics Inc.
Beta (Stock Volatility) N/A 0.25 N/A
Short % of Float 9.60% 15.76% Metsera Inc.

Metsera Inc. vs Corcept Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

MTSR
CORT

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Metsera Inc.0.00%-15.24%34.23%132.67%187.87%328.57%
Corcept Therapeutics Inc.2.04%9.00%40.79%105.92%-13.17%90.18%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Metsera Inc.166.04%166.04%166.04%166.04%166.04%166.04%
Corcept Therapeutics Inc.-10.40%198.75%224.57%1,093.99%1,292.59%1,378.51%

Performance & Financial Health Analysis: Metsera Inc. vs Corcept Therapeutics Inc.

MetricMTSRCORT
Market Information
Market Cap i$7.43B$4.84B
Market Cap CategoryMid capMid cap
10 Day Avg. Volume i7,401,3321,059,913
90 Day Avg. Volume i3,697,9111,702,484
Last Close$70.50$72.65
52 Week Range$12.30 - $83.86$28.66 - $91.00
% from 52W High-15.93%-20.16%
All-Time High$83.86 (Nov 07, 2025)$117.33 (Mar 31, 2025)
% from All-Time High-15.93%-38.08%
Growth Metrics
Quarterly Revenue GrowthN/A0.11%
Quarterly Earnings GrowthN/A-0.21%
Financial Health
Profit Margin (TTM) i0.00%0.13%
Operating Margin (TTM) i0.00%0.02%
Return on Equity (TTM) i-1.35%0.15%
Debt to Equity (MRQ) i0.840.94
Cash & Liquidity
Book Value per Share (MRQ)$3.21$6.11
Cash per Share (MRQ)$4.26$3.50
Operating Cash Flow (TTM) i$-231,428,000$142.00M
Levered Free Cash Flow (TTM) i$-121,201,504$114.19M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Metsera Inc. vs Corcept Therapeutics Inc.

MetricMTSR (Dec 03, 2025)CORT (Apr 22, 2026)
Price Ratios
P/E Ratio (TTM) i-34.7356.37
Forward P/E i-20.5828.05
PEG Ratio iN/A-2.72
Price to Sales (TTM) iN/A6.36
Price to Book (MRQ) i21.987.38
Market Capitalization
Market Capitalization i$7.43B$4.84B
Enterprise Value i$6.98B$4.43B
Enterprise Value Metrics
Enterprise to Revenue iN/A5.82
Enterprise to EBITDA i-26.3496.45
Risk & Other Metrics
Beta iN/A0.25
Book Value per Share (MRQ) i$3.21$6.11

Financial Statements Comparison: Metsera Inc. vs Corcept Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricMTSR (2024)CORT (2025)
Revenue/Sales i0761.41M
Cost of Goods Sold iN/A12.98M
COGS % of Revenue i-1.7%
Gross Profit iN/A748.43M
Gross Margin i-98.3%
Research & Development i107.52M254.91M
Operating Income (EBIT) i-134.31M44.80M
Operating Margin i-5.9%
EBITDA i-128.12M46.69M
EBITDA Margin i-6.1%
Pre-Tax Income i-218.47M66.46M
Pre-Tax Income % of Revenue i-8.7%
Income Tax i-9.34M-33.19M
Income Tax % of Revenue i--4.4%
Net Income (Profit) i-209.13M99.65M
Profit Margin i-13.1%

Balance Sheet & Liquidity Metrics

MetricMTSR (2024)CORT (2025)
Cash & Equivalents i352.45M120.50M
Total Current Assets i359.13M485.46M
Total Current Assets % of Revenue i-63.8%
Total Current Liabilities i67.31M166.09M
Total Current Liabilities % of Revenue i-21.8%
Long-Term Debt i701,0005.02M
Long-Term Debt % of Revenue i-0.7%
Total Shareholders Equity i287.35M647.81M
Retained Earnings i-257.15M643.39M
Retained Earnings % of Revenue i-84.5%
Property, Plant & Equipment i1.44M6.47M

Cash Flow Statement Comparison

MetricMTSR (2024)CORT (2025)
Operating Cash Flow i-111.82M160.91M
Operating Cash Flow % of Revenue i-21.1%
Capital Expenditures i-43,000-211,000
Free Cash Flow i-100.08M141.79M
FCF Margin i-18.6%
Debt Repayment iN/AN/A
Common Stock Repurchase iN/A0

Short Interest & Institutional Ownership Analysis

MetricMTSRCORT
Shares Short i4.77M12.45M
Short Ratio i2.526.68
Short % of Float i9.60%15.76%
Shares Outstanding i105.15M105.97M
Float Shares i64.78M87.88M
% Held by Insiders i13.04%11.54%
% Held by Institutions i90.24%72.17%
% Held by Public i-3.28%16.29%

Dividend Analysis & Yield Comparison: Metsera Inc. vs Corcept Therapeutics Inc.

MetricMTSRCORT
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A